Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Smithkline Beecham (SBH) -- Ignore unavailable to you. Want to Upgrade?

To: Dow Jones Reporter who wrote (20)	3/1/1998 2:01:00 PM
From: Zoltan!	Respond to of 61

exchange2000.com

To: Dow Jones Reporter who wrote (20)	3/7/1998 10:40:00 PM
From: Henry Niman	Respond to of 61

I have updated the SBH Alliance Table at home.att.net to include more details of the little molecule that mimics G-CSF (with exquisite specificity) as well as a few recently (1998) issued relevant patents.

To: Dow Jones Reporter who wrote (20)	3/9/1998 12:37:00 AM
From: Henry Niman	Respond to of 61

For more info, check out home.att.net It's a place for info on STATs and Ligand's mimics (so far it just has the info on the one for G-CSF). I have also linked it to Links to Ligand's front page at home.att.net

To: Dow Jones Reporter who wrote (20)	3/18/1998 9:50:00 AM
From: Henry Niman	Respond to of 61

Ligand (LGND) has signed a Leptin deal with SBH (and SBH has trimmed it's HGSI position). I think that this deal helps define SBH's direction in the future (toward STATs, including Leptin, G-CSF, and Epo) and away from Genomics. Details in Merger Table at home.att.net and the SBH Alliance & Biotech Boom Tables at: home.att.net

To: Dow Jones Reporter who wrote (20)	3/25/1998 9:29:00 AM
From: Henry Niman	Respond to of 61

Signals Magazine has done a review of Links to Ligand at: signalsmag.com Merger activity is mentioned in the article.

To: Dow Jones Reporter who wrote (20)	3/26/1998 7:20:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 61

Time for more merger mania? Jesse Eisinger in TSC ( thestreet.com ) has a piece on LLY. He is talking about additional downgrades and a possible sale. Details in the LLY Alliance table at home.att.net

To: Dow Jones Reporter who wrote (20)	3/27/1998 7:03:00 AM
From: Henry Niman	Respond to of 61

Last night LGND announced AHP's IND filing for TSE424. TSE424 is a SERM that will compete with SBH's Idoxifene, LLY's Evista (Raloxifene), and PFE's Droloxifene and CP-366,156. I have linked the press release to the AHP Alliance table at home.att.net as well as the TSE424 Clinical Trials table at home.att.net

To: Dow Jones Reporter who wrote (20)	4/3/1998 9:14:00 AM
From: Henry Niman	Respond to of 61

Lehman Bothers rates GLX OUTPERFORM and says GLX/SBH merger "still possible". Details in GLX and SBH Alliance tables at home.att.net